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to the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
neurotoxin to model dopaminergic degeneration. Mice null
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show a trend toward protection against this degeneration,
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receptors to regulate immune responses. The results place
further importance on the activation of PPARs and the neu-
roprotective roles these have in inﬂammatory processes
linked to neurodegenerative processes.  2015 The
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INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
a family of nuclear ligand-activated transcription factors
controlling a variety of genes with roles in lipid
metabolism, insulin sensitivity, fatty acid transport and
regulation of inﬂammation. They do this by binding to
speciﬁc peroxisome proliferator response elements in
enhancer sites of target genes. Initially identiﬁed in
Xenopus laevis, there are three mammalian isoforms –
PPARa, PPARd and PPARc – each with diﬀerent tissue
expression patterns and ligand aﬃnities (Desvergne and
Wahli, 1999).
Parkinson’s disease (PD) is a chronic progressive
disorder, characterized by the loss of dopaminergic
neurons in the nigrostriatal pathway (Dauer and
Przedborski, 2004), with symptoms including bradykine-
sia, resting tremor and postural instability. This pattern
of cell death can be reliably replicated using the 1-met
hyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neuro-
toxin. In the majority of cases the cause of the disease
is unknown, while the full pathology of the disease is not
understood. However, certain processes have been
implicated in the death of neurons, including inﬂamma-
tion, as shown through increased glial activity and
astrogliosis in PD brains (McGeer et al., 1988), while
MPTP also causes pathogenic upregulation of the
immune response (Kurkowska-Jastrzebska et al.,
1999). PPARc agonists provided neuroprotection in the
MPTP (Breidert et al., 2002; Dehmer et al., 2004;
Lecca et al., 2015; Pisanu et al., 2014; Barbiero et al.,
2014) and 6-hydroxydopamine (6-OHDA) model of PD
(Laloux et al., 2012; Sadeghian et al., 2012). The
PPARc agonist pioglitazone has been shown to inhibit
MPTP- and lipopolysaccharide (LPS)-induced neuronal
nuclear factor kappaB activation (Dehmer et al., 2004;
Lecca et al., 2015), and PPARc agonists reduced
MPTP-induced tumor necrosis factor-alpha (TNF-a and
interleukin (IL)-1b expression (Pisanu et al., 2014), and
LPS-induced neuronal cyclo-oxygenase-2, TNF-a, IL-
1b and IL-6 expression, thus providing protection
(Luna-Medina et al., 2005).
However, the picture is not quite as clear for PPARd,
as an agonist of this receptor had no eﬀect in the 6-
OHDA model (Sadeghian et al., 2012), but provided/licenses/by/4.0/).
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2007; Martin et al., 2013). In general, PPARd agonists
seem to be capable of protecting against oxidative stress
and neuroinﬂammation (reviewed in (Schnegg and
Robbins, 2011)).
Herein, we wanted to address the role of neuronal
PPAR expression in the neurodegenerative process of
PD using the MPTP-model. Mice with neuron-speciﬁc
disruption of PPARc and PPARd coding regions were
administered MPTP and measures of dopaminergicFig. 1. Immunolocalisation of PPARc and PPARd in the SNpc of genetically
conﬁrms the presence of PPARc (i–iii; green) and PPARd (iv–vi; green) with
protein is expressed without the gene being excised (PPARc: vii–ix; PPARd: x
knock-out (xix–xxi), while PPARd remains unaﬀected (xxii–xxiv). PPARd show
reduced (xxviii–xxx), while PPARc is unaﬀected (xxv–xxvii). In the double k
reduced and neurons show a change of morphology (xxxi–xxxiii and xxxiv–xx
in this ﬁgure legend, the reader is referred to the web version of this article.neuron survival assessed, thereby evaluating the role of
these receptors in neuroprotection.EXPERIMENTAL PROCEDURES
Generation of conditional knock-outs
Mice null for one or both of PPARd and PPARc were
generated using the Cre-lox technique, under the control
of a neuronal promoter (Barak et al., 1999, 2002).altered mice following MPTP treatment. Double immunoﬂuorescence
TH (red) in wild-type mice. The receptors remain visible when the Cre
vi–xviii). Fluorescence of PPARc is greatly reduced in the conditional
s a stronger presence in its knock-out model but expression appears
nock-out images expression of TH in dopaminergic neurons seems
xvi). Scale bar = 50 lm. (For interpretation of the references to color
)
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bred onto a wild-type C57Bl/6 background and cross-
bred to generate combinations of PPARc-null with or with-
out Nestin Cre and PPARd-null with or without Nestin Cre.
These generations were then cross-bred to produce a
double knock-out: PPARc-null-PPARd-null with Nestin
Cre (PPARcck//PPARdck/), before the resultant
double-knock-out mice were bred together to increase
the proportion of these with each generation. Nestin
Cre-negative mice were added at alternate generations
to maintain the optimum health of animals. It was ensured
that littermates did not breed together.
Genotypes were conﬁrmed by reverse transcription
polymerase chain reaction (RT-PCR) using the Go Taq
ampliﬁcation system (Promega, Southampton, UK), as
per manufacturer’s instructions, following DNA
extraction from ear clips and immunoﬂuorescence
staining of the receptors (Figs. 1 and 2).
Earclips of mice were taken and DNA samples
extracted using DNAreleasy (Anachem, Luton, UK),
following manufacturer’s instructions. Genotyping was
performed by RT-PCR using the Go Taq ampliﬁcation
system (Promega, Southampton, UK) as per
manufacturer’s instructions, with reaction mixture details
in Table 1.Fig. 2. DNA electrophoresis of transgenic mice. Genotypes of mice
were ascertained by measuring the band size of DNA extracts
following PCR in the presence of speciﬁc primers.
Table 1. RT-PCR reaction mixture for genotyping
Reaction mixture
4 ll 5 Go Taq Green reaction buﬀer
2 ll 2 mM dNTPs
1 ll of each primer
0.1 ll of Taq polymerase (5 U/ll)
1 ll DNA
Total volume adjusted to 20 ll with sterile distilled waterThe information regarding primers and their
sequences, annealing temperatures and electrophoresis
bands are detailed in Table 2. All PCR cycles were
subject to a hot-start (94–95 C). For Nestin Cre cycle
PCR conditions were 35 cycles of 94 C for 30 s, 51 C
for 60 s and 72 C for 60 s. For PPARc and PPARd
conditions were 35 cycles of 94 C for 20 s, 60 C for 30
s and 71.5 C for 70 s. Products were electrophoresed
on a 2% agarose gel and visualized with ethidium
bromide (ﬁnal concentration 0.1%) using the Alpha
Innotech digital imaging system (San Leandro, CA, USA).
Mutant mice, in terms of their phenotype, were
generally smaller at birth. This was a pattern noticed
with PPARd KO mice, so the phenotype diﬀerence is
likely due to a downstream eﬀect of this receptor.Animal treatments
Twelve-week-old male C57Bl/6 mice, PPARc and
PPARd-genetically altered mice received intraperitoneal
injections of MPTPHCl (30 mg/kg free base), dissolved
in 0.9% saline solution, one injection per day for ﬁve
consecutive days, before being sacriﬁced by
decapitation 21 days after the last injection. Control
mice received saline only. This treatment was in
accordance with the published guidelines (Jackson-
Lewis and Przedborski, 2007). All procedures were in
accordance with the Animals (Scientiﬁc Procedures) Act
1986 and were approved by the Home Oﬃce, Dundee,
UK.Immunohistochemistry and stereology
Brains were ﬁxed and processed for immunostaining as
described previously (Teismann et al., 2003; Sathe
et al., 2012). Primary and secondary antibodies used were
rabbit anti-tyrosine hydroxylase (TH) (1:1000; Millipore,
Watford, UK) and biotinylated goat anti-rabbit (1:200;
Vector Laboratories, Peterborough, UK). Immunostaining
was visualized with 3,30-diaminobenzidine (Sigma–
Aldrich, Poole, UK; 25 mg in 50 ml 0.1 M Tris GN pH 7.6
with 100 ll ammonium chloride (40 mg/200 ll Tris GN),
150 ll glucose oxidase (30 mg/10 ml Tris GN) and
400 ll glucose (200 mg/800 ll Tris GN)). Sections were
counterstained with Nissl reagent (thionin). The total
number of TH-positive neurons and Nissl-positive cells
in the substantia nigra pars compacta (SNpc) was
counted in the various groups of animals at 21 days after
the last MPTP or saline injection using the unbiased
optical fractionator method, as described previously
(Teismann et al., 2003; Sathe et al., 2012). Counting of
TH-positive cells was performed using regular light micro-
scopy (AxioImager M1, Carl Zeiss, Cambridge, UK) and
the optical fractionator method (West, 1993) (Stereo
Investigator Version 7, BMF Bioscience, Magdeburg,
Germany), while the observer was blinded to the subjects’
identity.
Striatal density of TH immunoreactivity was
determined as described previously (Wu et al., 2002)
and assessed on scans (Hewlett Packard Scanjet
G3110, Bracknell, Berkshire, UK) of the sections using
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USA).Immunoﬂuorescence
Immunoﬂuorescent staining was performed as described
(Teismann et al., 2003; Sathe et al., 2012). Sections were
washed three times for 5 min with 0.1% Triton X in 0.1 M
phosphate-buﬀered saline (PBS), before non-speciﬁc
binding was blocked with 10% normal goat serum in
0.1 M PBS-Triton X (PBS-T). Sections were incubated
overnight at 4 C in 0.1 M PBS-T with primary antibodies
as follows: rabbit anti-TH (1:1000; Millipore), PPARc
(1:100, Alexis Biochemicals, San Diego, CA, USA),
PPARd (1:250, Abcam, Cambridge, UK). Following fur-
ther washes, immunostaining was visualized with Alexa
Fluor 488 anti-rabbit or anti-mouse (1:300; Molecular
Probes, Eugene, OR, USA) or cy-3 anti-rabbit or anti-
mouse (1:200; Jackson ImmunoResearch, West Grove,
PA, USA) antibodies. After three ﬁnal washes, sections
were mounted on slides with Mowiol-DABCO.
Immunostaining was visualized by confocal microscopy
(LSM 510 or LSM 700, Carl Zeiss).High performance liquid chromatography (HPLC)
HPLC with electrochemical detection was used to
measure striatal levels of dopamine and 3,4-
dihydroxyphenylacetic acid (DOPAC) using a method
that has been described (Nuber et al., 2008).Statistical analysis
Data were analyzed in IBM SPSS Statistics Version 21 for
Windows (Hampshire, UK). All values are expressed as
the mean ± SEM. In the case of TH-numbers, Nissl
counts and striatal optical density normal distribution of
the data was tested and conﬁrmed with the Shapiro–
Wilk test. Homogeneity of variance was assessed by
Levene’s Test for Equality of Variance. For data sets,
two-way analysis of variance (ANOVA) was used to
assess diﬀerences among means, with genotype and
treatment as the independent factor. When ANOVA
showed signiﬁcant diﬀerences, Tukey’s post hoc testingTable 2. Primers for genotyping. (Primers were purchased from Sigma–Aldric
Target Primer Type Sequence (50-30)
Nestin
Cre
Wild-type Forward primer CTAGGCCACAGAATTGAA
Reverse primer GTAGGTGGAAATTCTAGC
Transgene Forward primer GCGGTCTGGCAGTAAAAA
Reverse primer GTGAAACAGCATTGCTGT








GTCGAGAAGTACTAGTGGwas used to make comparisons between means. As not
all groups are reported, we also assessed the
diﬀerences among means with genotype as the
independent factor in the two diﬀerent treatment groups,
followed by Newman–Keuls post hoc test. In the case of
dopamine and DOPAC levels normal distribution of the
data was tested and conﬁrmed for logarithmized values
with the Shapiro–Wilk test. Outliers were eliminated
based on descriptive statistics performed by SPSS.
Data are represented in non-log format for better
understanding. When ANOVA showed signiﬁcant
diﬀerences, Tukey’s post hoc testing was used to make
comparisons between means. As not all groups are
reported, we also assessed the diﬀerences among
means with genotype as the independent factor in the
two diﬀerent treatment groups, followed by Newman–
Keuls post hoc test. The null hypothesis was rejected at
the 0.05 level.
RESULTS
To assess the precise contribution that the two receptors
may have in a neuroprotective mechanism in PD, the
transgenic mice were injected with the MPTP neurotoxin.
Numbers of TH immunoreactive and Nissl-positive cells
were stereologically counted (Fig. 3). A two-way ANOVA
was conducted to assess the eﬀect of genotype and
treatment on numbers of TH-immunoreactive neurons
and Nissl-positive cells. There was a statistically
signiﬁcant interaction between genotype or treatment on
numbers of TH-positive neurons as well as Nissl-positive
cells. To assess the eﬀect of genotype on MPTP-induced
cell loss, a one-way ANOVA was performed and, as
expected, MPTP caused a signiﬁcant degeneration of
TH-positive neurons in both wild-type (p< 0.001, a one-
way ANOVA followed by Newman–Keuls post hoc test)
and PPARcck//PPARdck/ mice (p< 0.01, a one-way
ANOVA followed by Newman–Keuls post hoc test),
compared to their saline-treated controls of the same
genotype. MPTP also caused a signiﬁcant degeneration
of Nissl-positive cells in both wild-type (p< 0.001, a one-
way ANOVA followed by Newman–Keuls post hoc test)
and PPARcck//PPARdck/ mice (p< 0.001, a one-
















Fig. 3. Eﬀect of PPARc and/or PPARd conditional knock-out on
MPTP toxicity. (A) Representative photomicrograph images of saline-
and MPTP-treated SNpc sections. Scale bar = 200 lm. (B) MPTP
signiﬁcantly reduces levels of TH-positive neurons in the SNpc of both
wild-type (WT) and double knock-out (PPARcck//PPARdck/) mice.
When this group is compared to PPARc or PPARd single conditional
knock-out mice there is no signiﬁcant change. There is also no
diﬀerence between PPARcck//PPARdck/ and mice with the target
genes ﬂoxed (PPARcck and PPARdck). (C) Loss of Nissl-positive cells
conﬁrmed that the loss of TH-positive neurons corresponds to an
actual loss of neurons. Data are mean ± SEM, n= 3–9 per group.
**p< 0.01, ***p< 0.001, compared to saline-treated group of same
genotype; ##p< 0.01, ###p< 0.001, compared to MPTP-treated
groups (one-way ANOVA followed by Newman–Keuls post hoc test)
(TH – tyrosine hydroxylase; SNpc – substantia nigra pars compacta).
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genotype. No signiﬁcant change in MPTP-induced celldeath was evident 21 days after toxin treatment when
double knock-out mice were compared with mice with a
single knock-out of PPARc or PPARd or PPAR ﬂoxed
mice without a target gene excised. It is possible to
argue that higher numbers of PPARcck//PPARdck/
MPTP-treated brains could yield statistically signiﬁcant
results in this comparison since a pattern seems to show
that double knock-out mice are slightly more sensitive to
toxin-induced cell death.
To measure the impact on striatal ﬁbers which
innervate these bodies, TH density staining was
assessed. MPTP reduced TH innervation of the striatum
across all genotypes. The MPTP-treated double knock-
out brains have the lowest mean striatal density.
Following the pattern of nigral TH immunoreactivity
(Fig. 4A, B), the striatal densities of ﬂoxed and single
PPARc or PPARd knock-out mice appear higher, but
the diﬀerences are not signiﬁcant.
Levels of striatal monoamine were determined using
HPLC analysis (Fig. 4C, D). Across values of dopamine
and its metabolite DOPAC, signiﬁcant diﬀerences were
not found between MPTP-treated
PPARcck//PPARdck/ mice and those with one or
both of PPARc and PPARd genes left intact, but the
mean value for the double knock-out mice remains
lowest of all treatment groups. There was a statistically
signiﬁcant interaction between genotype or treatment on
striatal dopamine content (a two-way ANOVA followed
by Tukey post hoc test). To assess the eﬀect of
genotype alone on MPTP-treatment a one-way-ANOVA
was performed. There are signiﬁcant diﬀerences in
dopamine levels between saline-treated wild-type
(p< 0.001, a one-way ANOVA followed by Newman–
Keuls post hoc test), PPARcck and PPARcck/
(p< 0.01, a one-way ANOVA followed by Newman–
Keuls post hoc test) and their MPTP-infused littermates,
while DOPAC levels are diminished when MPTP is
administered to wild-type and PPARcck mice compared
to their saline-treated equivalents (p< 0.01, a one-way
ANOVA followed by Newman–Keuls post hoc test).
Staining was performed on mice treated with MPTP of
all genotypes to give an indication of knock-out success
(Fig. 1). Both receptors are clearly visible following
double immunoﬂuorescence of PPARc (i–iii; green) or
PPARd (iv–vi; green) with TH (red) in wild-type mice.
PPARc is present in a peri-nuclear location and PPARd
is found in the nuclei of neurons. This presence is
maintained when the Cre recombinase protein is
expressed without the gene being excised (PPARc: vii–
ix; PPARd: xxii–xxiv). When mice null for the gene are
compared with Cre+ mice, the expression of the
relevant gene is diminished. Fluorescence of PPARc is
greatly reduced in conditional knock-out mice (xiii–xv),
while PPARd remains unaﬀected (xvi–xviii). PPARd
appears to remain at a relatively high expression level in
its knock-out model (xxviii–xxx), but at a diminished
level, while PPARc is unaﬀected (xxv-xxvii). This may
be due to a form of Cre mosaicism in this particular
group, diﬃcult to detect with standard genotyping. In the
double knock-out images, both receptors, particularly
PPARc, show greatly reduced expression and TH cell
Fig. 4. Striatal dopaminergic innervation and dopamine and DOPAC content of PPARc and PPARd genetically manipulated mice. (A)
Representative scanned images of striatal sections following saline or MPTP administration. (B) MPTP signiﬁcantly reduces the density of striatal
sections when the double knock-out and wild-type mice are compared with the corresponding saline-treated sections. Single knock-out or mice with
the target gene ﬂoxed without PPARc or PPARd excised show no signiﬁcant variation from the PPARcck//PPARdck/ mice. (C) Genotype does
not signiﬁcantly aﬀect striatal dopamine levels but wild-type, PPARck and PPARck/ values are reduced following MPTP administration. (D) Striatal
DOPAC levels are also unaﬀected by genetic manipulation but wild-type and PPARck values are again reduced following MPTP administration. Data
are mean ± SEM, n= 3–9 per group. #p< 0.05, ###p < 0.001, compared to saline-treated group of same genotype (a one-way ANOVA followed
by Newman–Keuls post hoc test).
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xxxiv–xxxvi). Overall TH-positive neuron numbers
appear lower, as would be predicted from the
stereological data shown above.DISCUSSION
This study aimed to assess the contributions of PPARc
and PPARd in MPTP toxicity. Previous work through the
use of receptor-speciﬁc ligands has delineated the
neuroprotective eﬀects that activation of these receptors
has in several models of neurodegeneration. There is
evidence that they are likely to work through negative
modulation of immune responses through the inhibition
of pro-inﬂammatory cytokine release (Bishop-Bailey and
Bystrom, 2009). To consider the relative roles of the two
receptor subtypes and their contributions to such amechanism we generated single and double knock-out
mice of both PPAR isoforms. It was necessary to generate
double knockouts of PPARc and PPARd as PPAR iso-
forms are known to be subject to functional compensation
(Patsouris et al., 2006). Importantly, this compensatory
change is known to occur in neurons (Gonzalez-Aparicio
et al., 2011). Conditional knock-outs were required as a
complete knock-out of either receptor is lethal. Studies
by Barak and colleagues have investigated the viability of
PPARc/ and PPARd/ mice (Barak et al., 1999,
2002). Inducing PPARc deﬁciency through homologous
recombination causes death at two independent develop-
mental points, both of which result in embryonic death by
day 10 (Barak et al., 1999). Similarly, PPARd-deﬁciency
results in a high degree of embryonic lethality (over 90%)
with surviving mice smaller then wild-type counterparts,
while oﬀspring of these mice typically do not survive to full
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subsequently found that PPARd is a critical molecular sig-
naling link during the processes of maternal implantation
and decidualization, with embryonic expression of the
receptor required for placentation (Wang et al., 2007).
The Cre-lox P method, a technique pioneered by Sauer
and Henderson (1988), was utilized to produce tissue-
speciﬁc knock-outs of the gene products to avoid the
lethality which aﬀects complete PPARc and PPARd
knock-outs. Still, by using the knockout technique, muta-
tion occurs systemically. Speciﬁcally silencing PPARd
and/or PPARc in the SNpc or striatum could be a further
useful approach to delineate the function of these PPAR
isoforms.
Oﬀspring of several genotypes were administered
MPTP before assessing neurodegeneration. Numbers of
TH-positive cells were lowest in the PPARcck//
PPARdck/ group of mice, although this number did not
vary signiﬁcantly from that shown by single knock-out or
ﬂoxed mice. The relatively even number of cells across
the PPARcck/ and PPARdck/ groups may indicate
equally signiﬁcant contributions to processes underlying
overall neuron survival from activation of these receptor
subtypes. Furthermore, a lower mean TH-positive cell
count among PPARcck//PPARdck/ mice potentially
indicates a degree of functional compensation that may
acquire increased importance when expression of one
receptor is lower than physiological levels. As PPARc
and PPARd can also be expressed by glial cells, it
seems more likely that the expression of PPARs on
these cells is more relevant to the overall eﬀect of
PPAR-mediated eﬀects in the MPTP-model. The trend
observed in neuron cell bodies was adhered to in other
measurements of dopaminergic cell loss. The density of
TH-positive ﬁber projection to the striatum showed an
identical pattern to that of nigral TH-positive neurons,
while striatal dopamine and DOPAC levels, measured
by HPLC, demonstrated similar results. All genotypes
express lower dopamine levels, although not to a
signiﬁcant extent. This could be an eﬀect of the genes
involved which, despite not being active, might still
have an impact on overall dopamine content. Wild-
type mice show similar levels of TH-positive cells
compared to the single receptor knock-out or ﬂoxed
mice. This may be due to a functional compensation
of the PPAR isoforms to levels where physiological
neuroprotective mechanisms are maintained. Further
studies should address whether the observed changes
also translate to functional changes using appropriate
behavioral tests.
It has been shown that heterozygous PPARd mice
maintain levels of protein relative to that of wild-type
mice despite having approximately half the PPARd
mRNA, thereby indicating PPARd has a vital function in
the basal activity of neurons (Martin et al., 2013). The
importance of PPARd has been proposed previously, with
evidence the isoform acts as a ‘gateway receptor’, as
stable expression of the PPARd inhibits that of PPARc
and modulates its function (Shi et al., 2002). As noted
above, the levels of dopaminergic cell survival were rela-
tively equal in PPARcck/ and PPARdck/ mice. Thisindicates that PPARd may play no particular importance
in the regulation of inﬂammation over the PPARc isoform.
However, there is an absence of statistical
signiﬁcance in the results, likely due in part to the low
numbers of PPARcck//PPARdck/, a result of the
diﬃculty in producing these mice in the time-frame of
the study. The work, nonetheless, provides compelling
initial genetic evidence that backs up pharmacological
studies supporting the importance in PPAR activation in
neuronal survival. Pharmacological antagonism of both
receptors has independently proven to reduce cell
survival. The selective PPARd antagonist GSK0660 can
exacerbate 1-methyl-4-phenylpyridinium (MPP)+-induced
cell death in vitro (Martin et al., 2013). A selective
antagonist of PPARc, bisphenol A diglycidyl ether, causes
deteriorating clinical performance in a model of multiple
sclerosis (Raikwar et al., 2005). Another antagonist at this
receptor subtype, GW9662, augmented MPTP-induced
loss of TH-positive neuron in mice (Martin et al., 2012),
demonstrating that activation of these receptors may be
important in protection against inﬂammatory insult.
Indeed, there are many studies providing signs that
PPARc and PPARd activation is important in mediating
neuroprotection. Investigations of the PPARc agonists
pioglitazone (Breidert et al., 2002; Dehmer et al., 2004),
rosiglitazone (Schintu et al., 2009; Martin et al., 2012;
Pisanu et al., 2014) and the non-thiazolidinedione
MDG548 (Lecca et al., 2015) have provided evidence that
these agents can attenuate MPTP-induced neuronal loss
in the SNpc. The thiazolidinedione pioglitazone is able to
restore mitochondrial function following administration of
the bacterial endotoxin LPS in rats (Hunter et al., 2007).
This particular action may be through an upregulation of
anti-apoptotic protein Bcl-2 (Fuenzalida et al., 2007), which
can inhibit the opening of mitochondrial permeability pores
(Zorov et al., 2009). Furthermore, additional experiments
need to demonstrate if PPAR agonists provide protection
in a regional-speciﬁc model of PD, such as the lentiviral-
based delivery of a-synuclein (Lo et al., 2002), thus
demonstrating the relevance of PPARs as a potential neu-
roprotective therapy. It would also be useful to assess the
impact of silencing these receptors in a speciﬁc region,
such as SNpc or even the striatum.
In all cases protection occurs alongside a reduction in
the immune response as microglial and astrocyte
activation is reduced. PPARc agonists can reduce
inﬂammatory responses including production of TNFa
and inducible nitric oxide synthase (iNOS) (Breidert
et al., 2002). Both these processes have been implicated
in the death of dopaminergic neurons (Boka et al., 1994;
Hunot et al., 1996). In addition, PPARc activation led to
a reduction of MPTP-induced nitrotyrosine levels, a mar-
ker for NO-mediated damage (Dehmer et al., 2004), and
reduced MPTP-mediated increase in iNOS expression
(Lecca et al., 2015). A possible antioxidant role of
PPARc activation is supported by our own group, as we
demonstrated that rosiglitazone attenuates reactive oxy-
gen species (ROS) formation induced by MPP+ in vitro
(Martin et al., 2012). This may be through upregulation
of superoxide dismutase (SOD) and catalase expression
(Jung et al., 2007). Alterations in PPAR expression also
R. B. Mounsey et al. / Neuroscience 300 (2015) 576–584 583supplement the hypothesis that the presence of the
PPARc and PPARd subtypes together is important in
neuroprotection. Both the mRNA and protein levels of
PPARc in the ventral midbrain are upregulated 7 days
after MPTP treatment (Martin et al., 2012). Similarly,
PPARd mRNA and protein levels show an immediate
upregulation in the striatum (Martin et al., 2013). These
expression alterations may represent an endogenous
defence mechanism against the inﬂammatory and oxida-
tive insults of MPTP – a mechanism that
PPARcck//PPARdck/ mice are likely devoid of, lead-
ing to reduced neuron survival. Furthermore, endogenous
ligands of the PPARs may have a role. The structure of
these receptors allow for the binding of an array of
ligands, including fatty acids, eicosanoids and steroids.
The impact these could have on this mechanism is not
currently known.
It would be interesting to investigate the protective
abilities of PPAR agonists in knock-out animals to test
whether the beneﬁts shown by these agents are
dependent upon receptor activation or can be initiated
independently of the receptor.
Biological eﬀects following administration of agonists
that are not dependent upon PPARc activation, such as
antioxidant beneﬁts, have a signiﬁcant impact upon
neuroprotection (Davies et al., 2001; Chintharlapalli
et al., 2005; Wang et al., 2011; Martin et al., 2012). The
use of agonists may have an inﬂuence on cellular meta-
bolic function as pioglitazone could increase glucose
uptake by cells, thereby increasing their resistance to
MPTP (Breidert et al., 2002). It remains to be seen
whether these same pro-inﬂammatory mediators are
inhibited without the direct action of the ligand, but this
study further underlines the importance of PPAR path-
ways in models of neuronal degeneration.
CONCLUSION
Neuronal PPARc or PPARd does not seem to counteract
MPTP-induced toxicity. Diﬀerent aspects need to be
taken into account to explain the ﬁndings. The results
might be due to the fact that ablation of the
neuronal receptors was not 100% complete, but were
below the level to be picked up using PCR and
immunohistochemistry. Since PPARs are also
expressed on glial cells, it may be argued that the main
protective role of PPARs is played by glial receptors
rather than neuronal, an aspect which needs further
investigation.
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